<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="325b33cd-730b-26a4-e063-6294a90a7a4b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use 
  <content styleCode="bold">THYQUIDITY 
   <sup>®</sup>
         </content>safely and effectively. 
  <content styleCode="bold"> See full prescribing information for 
   <content styleCode="bold">
               <content styleCode="bold">THYQUIDITY 
     <sup>®</sup>
               </content>
            </content>. 
  </content>
      </content>
      <br/>
      <br/>
      <content styleCode="bold">
         <content styleCode="bold">
            <content styleCode="bold">THYQUIDITY 
    <sup>®</sup>
            </content>
         </content> (levothyroxine sodium) oral solution 
 </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2000</content>
   </title>
   <effectiveTime value="20250409"/>
   <setId root="c17ec992-a122-4cd9-8469-d91255c32440"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117505635"/>
            <name>Azurity Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="506970191"/>
                        <name>Galenica S.A.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="327335410"/>
                        <name>Peptido, chemische und pharmazeutische Rohstoffgesellschaft mit beschränkter Haftung</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="325b7e63-e638-4112-e063-6394a90aa1ff"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250409"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="52652-1950" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>THYQUIDITY</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levothyroxine Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CR6K9C2NHK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="ug" value="100"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="2" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="52652-1950-2" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20230405"/>
                                                <high value="20251031"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="52652-1950-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230405"/>
                                          <high value="20251031"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214047" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230405"/>
                              <high value="20251031"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_b7e90274-8447-41bf-8803-c34d58d232cd">
               <id root="325b33cd-730c-26a4-e063-6294a90a7a4b"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects
  
   <content styleCode="italics">[see</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_a17ac771-3438-42d9-a31e-b746f99324f4">Adverse Reactions (6)</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">,</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_d0bdc43b-cccb-4bcf-a587-a0be23409678">Drug Interactions (7.7)</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">, and</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_d0f93798-efb2-4b47-b48d-8cc5f9769383">Overdosage</linkHtml>
                              </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_d0f93798-efb2-4b47-b48d-8cc5f9769383">(10)</linkHtml>
                              </content>
                           </content>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">]</content>
                     </content>
                     <content styleCode="bold">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Thyroid hormones, including THYQUIDITY, should not be used for the treatment of obesity or for weight loss.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (</content>
                              <content styleCode="bold">
                                 <linkHtml href="#LINK_a17ac771-3438-42d9-a31e-b746f99324f4">6</linkHtml>,
  
     </content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">
                                 <linkHtml href="#LINK_d0f93798-efb2-4b47-b48d-8cc5f9769383">10</linkHtml>).
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_00108012-715a-415a-8f6b-a245260c7faa">
               <id root="325b33cd-730d-26a4-e063-6294a90a7a4b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Hypothyroidism</content>
                  </paragraph>
                  <paragraph>THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression</content>
                  </paragraph>
                  <paragraph>THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with THYQUIDITY may induce hyperthyroidism
  
   <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_74077141-e4b4-4b01-aceb-fa6b044ec25a">Warnings and Precautions (5.4)</linkHtml>
                        </content>
                        <content styleCode="italics">].</content>
                     </item>
                     <item>THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.</item>
                  </list>
               </text>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>THYQUIDITY is levothyroxine sodium (T4) indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
  
     <linkHtml href="#LINK_00108012-715a-415a-8f6b-a245260c7faa">(1)</linkHtml>
                           </item>
                           <item>Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
  
     <linkHtml href="#LINK_00108012-715a-415a-8f6b-a245260c7faa">(1)</linkHtml>
                              <paragraph>
                                 <content styleCode="underline">Limitations of Use:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <paragraph>Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients 
        <br/>
                                    </paragraph>
                                 </item>
                                 <item>Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_b7670df4-1d1f-4947-9520-25e5f0643ddb">
               <id root="325b33cd-730e-26a4-e063-6294a90a7a4b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. 
  
     <linkHtml href="#LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">(2.1)</linkHtml>
                           </item>
                           <item>Administer at least 4 hours before or after drugs that are known to interfere with absorption.
  
     <linkHtml href="#LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">(2.1)</linkHtml>
                           </item>
                           <item>Administer orally using syringe provided by the pharmacy 
  
     <linkHtml href="#LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">(2.1)</linkHtml>
                           </item>
                           <item>Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect THYQUIDITY absorption.
  
     <linkHtml href="#LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">(2.1)</linkHtml>
                           </item>
                           <item>Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated. Peak therapeutic effect may not be attained for 4-6 weeks.
  
     <linkHtml href="#LINK_47771336-925b-4c40-bd0f-f486a7303bae">(2.2)</linkHtml>
                           </item>
                           <item>See full prescribing information for dosing in specific patient populations.
  
     <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">(2.3)</linkHtml>
                           </item>
                           <item>Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status.
  
     <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">(2.4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">
                     <id root="325b33cd-730f-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Administration Information</title>
                     <text>
                        <paragraph>Administer THYQUIDITY as a single daily oral dose, on an empty stomach, one-half to one hour before breakfast.</paragraph>
                        <paragraph>Administer THYQUIDITY at least 4 hours before or after drugs known to interfere with THYQUIDITY absorption
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5d5e4f02-3476-419a-b086-245a22816756">Drug Interactions (7.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect THYQUIDITY absorption
 
  <content styleCode="italics">[see 
  
   <content styleCode="italics">
                                 <linkHtml href="#LINK_5dc96214-ec31-46fe-8016-dbbfd3873d39">Drug Interactions (7.9)</linkHtml>
                              </content> 
 
  </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#LINK_695fc817-660b-489c-a414-c05d073bd7f3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>Administer THYQUIDITY directly to the mouth using a calibrated oral syringe provided by the pharmacy. A household teaspoon or tablespoon is not an adequate measuring device.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_47771336-925b-4c40-bd0f-f486a7303bae">
                     <id root="325b33cd-7310-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 General Principles of Dosing</title>
                     <text>
                        <paragraph>The dose of THYQUIDITY for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">Dosage and Administration (2.3)</linkHtml>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_7ea52931-fc46-4a6d-b71e-6bd33fb5c8d7">Warnings and Precautions (5)</linkHtml>
                           </content>, and
 
  <content styleCode="italics">
                              <linkHtml href="#LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">Dosage and Administration (2.4)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>The peak therapeutic effect of a given dose of THYQUIDITY may not be attained for 4 to 6 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">
                     <id root="325b33cd-7311-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosing in Specific Patient Populations</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Primary Hypothyroidism in Adults and in Adolescents in Whom Growth and Puberty are Complete</content>
                        </paragraph>
                        <paragraph>Start THYQUIDITY at the full replacement dose in otherwise healthy, non-elderly individuals who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of THYQUIDITY is approximately 1.6 mcg per kg per day (for example: 100 to 125 mcg per day for a 70 kg adult).</paragraph>
                        <paragraph>Adjust the dose by 12.5 to 25 mcg increments every 4 to 6 weeks until the patient is clinically euthyroid and the serum TSH returns to normal. Doses greater than 200 mcg per day are seldom required. An inadequate response to daily doses of greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.</paragraph>
                        <paragraph>For elderly patients or patients with underlying cardiac disease, start with a dose of 12.5 to 25 mcg per day. Increase the dose every 6 to 8 weeks, as needed, until the patient is clinically euthyroid and the serum TSH returns to normal. The full replacement dose of THYQUIDITY may be less than 1 mcg per kg per day in elderly patients.</paragraph>
                        <paragraph>In patients with severe longstanding hypothyroidism, start with a dose of 12.5 to 25 mcg per day. Adjust the dose in 12.5 to 25 mcg increments every 2 to 4 weeks until the patient is clinically euthyroid and the serum TSH level is normalized.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Secondary or Tertiary Hypothyroidism</content>
                        </paragraph>
                        <paragraph>Start THYQUIDITY at the full replacement dose in otherwise healthy, non-elderly individuals. Start with a lower dose in elderly patients, patients with underlying cardiovascular disease or patients with severe longstanding hypothyroidism as described above. Serum TSH is not a reliable measure of THYQUIDITY dose adequacy in patients with secondary or tertiary hypothyroidism and should not be used to monitor therapy. Use the serum free-T4 level to monitor adequacy of therapy in this patient population. Titrate THYQUIDITY dosing per above instructions until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Dosage - Congenital or Acquired Hypothyroidism</content>
                        </paragraph>
                        <paragraph>The recommended daily dose of THYQUIDITY in pediatric patients with hypothyroidism is based on body weight and changes with age as described in Table 1. Start THYQUIDITY at the full daily dose in most pediatric patients. Start at a lower starting dose in newborns (0-3 months) at risk for cardiac failure and in children at risk for hyperactivity (see below). Monitor for clinical and laboratory response
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">Dosage and Administration (2.4)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. THYQUIDITY Dosing Guidelines for Pediatric Hypothyroidism</content>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="285.25pt"/>
                           <col width="184.2pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">AGE</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Daily Dose Per Kg Body Weight
      
       <sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0-3 months</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>10-15 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3-6 months</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8-10 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6-12 months</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6-8 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1-5 years</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5-6 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6-12 years</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4-5 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 12 years but growth and puberty incomplete</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2-3 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Growth and puberty complete</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.6 mcg/kg/day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <sup>a</sup>The dose should be adjusted based on clinical response and laboratory parameters
     
      <content styleCode="italics">[see</content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">Dosage and Administration (2.4)</linkHtml> 
     
      </content>and
     
      <content styleCode="italics">
                                          <linkHtml href="#LINK_9e0781b5-2d5c-4066-b626-2012142cd70f">Use in Specific Populations (8.4)</linkHtml>
                                       </content>
                                       <content styleCode="italics">]</content>.
    
     </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Newborns (0-3 months) at risk for cardiac failure</content>: Consider a lower starting dose in newborns at risk for cardiac failure. Increase the dose every 4 to 6 weeks as needed based on clinical and laboratory response.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Children at risk for hyperactivity</content>: To minimize the risk of hyperactivity in children, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full recommended replacement dose until the full recommended replacement dose is reached. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pregnancy</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pre-existing Hypothyroidism:</content>THYQUIDITY dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at a minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester- specific range, increase the dose of THYQUIDITY by 12.5 to 25 mcg/day and measure TSH every 4 weeks until a stable THYQUIDITY dose is reached and serum TSH is within the normal trimester-specific range. Reduce THYQUIDITY dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure THYQUIDITY dose is appropriate. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">New Onset Hypothyroidism</content>: Normalize thyroid function as rapidly as possible. Evaluate serum TSH every 4 weeks and adjust THYQUIDITY dosage until a serum TSH is within the normal trimester specific range
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_055dfa0d-f871-4d76-b12d-55af7dcfc70b">Use in Specific Populations (8.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">TSH Suppression in Well-differentiated Thyroid Cancer</content>
                        </paragraph>
                        <paragraph>Generally, TSH is suppressed to below 0.1 mIU per liter, and this usually requires a THYQUIDITY dose of greater than 2 mcg per kg per day. However, in patients with high-risk tumors, the target level for TSH suppression may be lower.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">
                     <id root="325b33cd-7312-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Monitoring TSH and/or Thyroxine (T4) Levels</title>
                     <text>
                        <paragraph>Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism, despite an apparent adequate replacement dose of THYQUIDITY, may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adults</content>
                           <br/>
                        </paragraph>
                        <paragraph>In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient's clinical status. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatrics</content>
                           <br/>
                        </paragraph>
                        <paragraph>In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in children as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dose stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals. 
  <br/>
                        </paragraph>
                        <paragraph>Although the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to
 
  <content styleCode="italics">in utero</content>hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of THYQUIDITY therapy and/or of the serum TSH to decrease below 20 mIU per liter within 4 weeks may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of THYQUIDITY 
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_74077141-e4b4-4b01-aceb-fa6b044ec25a">Warnings and Precautions (5.4)</linkHtml> 
 
  </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#LINK_9e0781b5-2d5c-4066-b626-2012142cd70f">Use in Specific Populations (8.4)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Secondary and Tertiary Hypothyroidism</content>
                           <br/>
                        </paragraph>
                        <paragraph>Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d1d06824-b92e-40c5-b373-2738fc8bbdb6">
               <id root="325b33cd-7313-26a4-e063-6294a90a7a4b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Oral Solution: 100 mcg per 5 mL (20 mcg per mL) clear, colorless to nearly colorless solution in 100 mL bottles</paragraph>
                  <paragraph>THYQUIDITY is to be used with a calibrated oral syringe provided by the pharmacy.</paragraph>
               </text>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Oral Solution: 100 mcg per 5 mL (20 mcg per mL) in 100 mL bottles
 
    <linkHtml href="#LINK_d1d06824-b92e-40c5-b373-2738fc8bbdb6">(3)</linkHtml>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_c934637e-3125-4e1a-b7ad-1c85e65dbc9e">
               <id root="325b33cd-7314-26a4-e063-6294a90a7a4b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>THYQUIDITY is contraindicated in patients with:</paragraph>
                  <list listType="unordered">
                     <item>Uncorrected adrenal insufficiency
  
   <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_a400a999-a945-4267-811f-6791af234b44">Warnings and Precautions (5.3)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Uncorrected adrenal insufficiency.
  
     <linkHtml href="#LINK_c934637e-3125-4e1a-b7ad-1c85e65dbc9e">(4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7ea52931-fc46-4a6d-b71e-6bd33fb5c8d7">
               <id root="325b33cd-7315-26a4-e063-6294a90a7a4b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease:</content>Initiate THYQUIDITY at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (
  
     <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">2.3</linkHtml>, 
  
     <linkHtml href="#LINK_0cf405ff-c6cf-4e5d-b10f-3c97b807a0d8">5.1</linkHtml>, 
  
     <linkHtml href="#LINK_edc4a133-7ee9-49df-96d9-fe5e69e854b2">8.5</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">Myxedema coma:</content>Do not use oral thyroid hormone drug products to treat myxedema coma.
  
     <linkHtml href="#LINK_1e96276d-68b6-4c1e-8d42-3ee42d08f74a">(5.2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Acute adrenal crisis in patients with concomitant adrenal insufficiency:</content>Treat with replacement glucocorticoids prior to initiation of THYQUIDITY treatment.
  
     <linkHtml href="#LINK_a400a999-a945-4267-811f-6791af234b44">(5.3)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Prevention of hyperthyroidism or incomplete treatment of hypothyroidism:</content>Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism.
  
     <linkHtml href="#LINK_74077141-e4b4-4b01-aceb-fa6b044ec25a">(5.4)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Worsening of diabetic control:</content>Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy.
  
     <linkHtml href="#LINK_b15fced1-2194-453b-9c57-07dc120c07d3">(5.5)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Decreased bone mineral density associated with thyroid hormone over- replacement:</content>Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose.
  
     <linkHtml href="#LINK_b9e5cb98-2a4b-4085-9510-8b6e5ce574c5">(5.6)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0cf405ff-c6cf-4e5d-b10f-3c97b807a0d8">
                     <id root="325b33cd-7316-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease</title>
                     <text>
                        <paragraph>Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate THYQUIDITY therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">Dosage and Administration (2.3)</linkHtml>, 
 
  </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_edc4a133-7ee9-49df-96d9-fe5e69e854b2">Use in Specific Populations (8.5)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive THYQUIDITY therapy. Monitor patients receiving concomitant THYQUIDITY and sympathomimetic agents for signs and symptoms of coronary insufficiency.</paragraph>
                        <paragraph>If cardiac symptoms develop or worsen, reduce the THYQUIDITY dose or withhold for one week and restart at a lower dose.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1e96276d-68b6-4c1e-8d42-3ee42d08f74a">
                     <id root="325b33cd-7317-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Myxedema Coma</title>
                     <text>
                        <paragraph>Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a400a999-a945-4267-811f-6791af234b44">
                     <id root="325b33cd-7318-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency</title>
                     <text>
                        <paragraph>Thyroid hormone increases metabolic clearance of glucocorticoids.  Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with THYQUIDITY 
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c934637e-3125-4e1a-b7ad-1c85e65dbc9e">Contraindications (4)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_74077141-e4b4-4b01-aceb-fa6b044ec25a">
                     <id root="325b33cd-7319-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism</title>
                     <text>
                        <paragraph>THYQUIDITY has a narrow therapeutic index. Over- or undertreatment with THYQUIDITY may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and glucose and lipid metabolism
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_9e0781b5-2d5c-4066-b626-2012142cd70f">Use in Specific Populations - Pediatric Use (8.4)</linkHtml>]
 
  </content>. Titrate the dose of THYQUIDITY carefully and monitor response to titration to avoid these effects
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">Dosage and Administration (2.4)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Monitor for the presence of drug or food interactions when using THYQUIDITY and adjust the dose as necessary
 
  <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5dc96214-ec31-46fe-8016-dbbfd3873d39">Drug Interactions (7.9)</linkHtml>
                           </content>
                           <content styleCode="italics">and</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_695fc817-660b-489c-a414-c05d073bd7f3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b15fced1-2194-453b-9c57-07dc120c07d3">
                     <id root="325b33cd-731a-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Worsening of Diabetic Control</title>
                     <text>
                        <paragraph>Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing THYQUIDITY 
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_29b4a1ff-c87c-492b-89a8-47a8c0c4bd31">Drug Interactions (7.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b9e5cb98-2a4b-4085-9510-8b6e5ce574c5">
                     <id root="325b33cd-731b-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement</title>
                     <text>
                        <paragraph>Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of THYQUIDITY that achieves the desired clinical and biochemical response to mitigate this risk.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a17ac771-3438-42d9-a31e-b746f99324f4">
               <id root="325b33cd-731c-26a4-e063-6294a90a7a4b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions associated with THYQUIDITY therapy are primarily those of hyperthyroidism due to therapeutic overdosage
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_7ea52931-fc46-4a6d-b71e-6bd33fb5c8d7">Warnings and Precautions (5)</linkHtml>
                     </content>,
 
  <content styleCode="italics">
                        <linkHtml href="#LINK_d0f93798-efb2-4b47-b48d-8cc5f9769383">Overdosage (10)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. They include the following:

 </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="italics">General:</content>fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
 
  </item>
                     <item>
                        <content styleCode="italics">Central nervous system:</content>headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
 
  </item>
                     <item>
                        <content styleCode="italics">Musculoskeletal:</content>tremors, muscle weakness, muscle spasm
 
  </item>
                     <item>
                        <content styleCode="italics">Cardiovascular:</content>palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
 
  </item>
                     <item>
                        <content styleCode="italics">Respiratory:</content>dyspnea
 
  </item>
                     <item>
                        <content styleCode="italics">Gastrointestinal:</content>diarrhea, vomiting, abdominal cramps, elevations in liver function tests
 
  </item>
                     <item>
                        <content styleCode="italics">Dermatologic:</content>hair loss, flushing, rash
 
  </item>
                     <item>
                        <content styleCode="italics">Endocrine:</content>decreased bone mineral density
 
  </item>
                     <item>
                        <content styleCode="italics">Reproductive:</content>menstrual irregularities, impaired fertility
 
  </item>
                  </list>
                  <paragraph>Seizures have been reported rarely with the institution of levothyroxine therapy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adverse Reactions in Children</content>
                  </paragraph>
                  <paragraph>Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.</paragraph>
               </text>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions associated with THYQUIDITY therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.
 
    <linkHtml href="#LINK_a17ac771-3438-42d9-a31e-b746f99324f4">(6)</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c">
               <id root="325b33cd-731d-26a4-e063-6294a90a7a4b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for drugs that affect thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, metabolism, protein binding, and target tissue response) and may alter the therapeutic response to THYQUIDITY.
 
    <linkHtml href="#LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c">(7)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_5d5e4f02-3476-419a-b086-245a22816756">
                     <id root="325b33cd-731e-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics</title>
                     <text>
                        <paragraph>Many drugs can exert effects on thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, metabolism, protein binding, and target tissue response) and may alter the therapeutic response to THYQUIDITY (see Tables 2-5 below).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2. Drugs That May Decrease T4 Absorption (Hypothyroidism)</content>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="469.5pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact: Concurrent use may reduce the efficacy of THYQUIDITY by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Calcium Carbonate Ferrous Sulfate</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric- thyroxine complex. Administer THYQUIDITY at least 4 hours apart from these agents.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Orlistat</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Monitor patients treated concomitantly with orlistat and THYQUIDITY for changes in thyroid function.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Bile Acid Sequestrants</paragraph>
                                    <paragraph>-Colesevelam</paragraph>
                                    <paragraph>-Cholestyramine</paragraph>
                                    <paragraph>-Colestipol</paragraph>
                                    <paragraph>Ion Exchange Resins</paragraph>
                                    <paragraph>-Kayexalate</paragraph>
                                    <paragraph>-Sevelamer</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer THYQUIDITY at least 4 hours prior to these drugs or monitor TSH levels.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Other drugs:</paragraph>
                                    <paragraph>Proton Pump Inhibitors</paragraph>
                                    <paragraph>Sucralfate</paragraph>
                                    <paragraph>Antacids</paragraph>
                                    <paragraph>- Aluminum &amp; Magnesium</paragraph>
                                    <paragraph>Hydroxides</paragraph>
                                    <paragraph>- Simethicone</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.</paragraph>
                                    <br/>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)</content>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="164.3pt"/>
                           <col width="305.2pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Clofibrate</paragraph>
                                    <paragraph>Estrogen-containing oral contraceptives</paragraph>
                                    <paragraph>Estrogens (oral)</paragraph>
                                    <paragraph>Heroin / Methadone</paragraph>
                                    <paragraph>5-Fluorouracil</paragraph>
                                    <paragraph>Mitotane</paragraph>
                                    <paragraph>Tamoxifen</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>These drugs may increase serum thyroxine-binding globulin (TBG) concentration.</paragraph>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Androgens / Anabolic Steroids Asparaginase</paragraph>
                                    <paragraph>Glucocorticoids</paragraph>
                                    <paragraph>Slow-Release Nicotinic Acid</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>These drugs may decrease serum TBG concentration.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact (below): Administration of these agents with THYQUIDITY results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Salicylates (&gt; 2 g/day)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Other drugs: Carbamazepine Furosemide (&gt; 80 mg IV)</paragraph>
                                    <paragraph>Heparin</paragraph>
                                    <paragraph>Hydantoins</paragraph>
                                    <paragraph>Non-Steroidal Anti-inflammatory Drugs</paragraph>
                                    <paragraph>-Fenamates</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.</paragraph>
                                    <paragraph>Closely monitor thyroid hormone parameters.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)</content>
                           <br/>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="469.5pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased THYQUIDITY requirements.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Phenobarbital</paragraph>
                                    <paragraph>Rifampin</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5. Drugs That May Decrease Conversion of T4 to T3</content>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="469.5pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Beta-adrenergic antagonists (e.g., Propranolol &gt; 160 mg/day)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>In patients treated with large doses of propranolol (&gt; 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Glucocorticoids</paragraph>
                                    <paragraph>(e.g., Dexamethasone
     
      <content styleCode="underline">&gt;</content>4 mg/day)
    
     </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Other drugs: Amiodarone</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decrease or normal free-T3) in clinically euthyroid patients.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_29b4a1ff-c87c-492b-89a8-47a8c0c4bd31">
                     <id root="325b33cd-731f-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Antidiabetic Therapy</title>
                     <text>
                        <paragraph>Addition of THYQUIDITY therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_b15fced1-2194-453b-9c57-07dc120c07d3">Warnings and Precautions (5.5)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3853d981-f436-43a6-9f2b-0b2042d85c20">
                     <id root="325b33cd-7320-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Oral Anticoagulants</title>
                     <text>
                        <paragraph>THYQUIDITY increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the THYQUIDITY dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c5a3d8f9-11e3-4530-9a31-0f05c6f1013c">
                     <id root="325b33cd-7321-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Digitalis Glycosides</title>
                     <text>
                        <paragraph>THYQUIDITY may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2e1c24be-003a-4f7f-abbb-231413d0ca06">
                     <id root="325b33cd-7322-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Antidepressant Therapy</title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and THYQUIDITY may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. THYQUIDITY may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on THYQUIDITY may result in increased THYQUIDITY requirements.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_31b2d769-0dc7-4d0d-b8a4-ab563a053c9d">
                     <id root="325b33cd-7323-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Ketamine</title>
                     <text>
                        <paragraph>Concurrent use of ketamine and THYQUIDITY may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d0bdc43b-cccb-4bcf-a587-a0be23409678">
                     <id root="325b33cd-7324-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Sympathomimetics</title>
                     <text>
                        <paragraph>Concurrent use of sympathomimetics and THYQUIDITY may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_531d2fe0-9032-40ee-a806-8e9937d14b6b">
                     <id root="325b33cd-7325-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.8 Tyrosine-Kinase Inhibitors</title>
                     <text>
                        <paragraph>Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5dc96214-ec31-46fe-8016-dbbfd3873d39">
                     <id root="325b33cd-7326-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.9 Drug-Food Interactions</title>
                     <text>
                        <paragraph>Consumption of certain foods may affect THYQUIDITY absorption thereby necessitating adjustments in dosing
 
  <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_e28adf2c-b17a-43f3-88a2-4a53f0d09d1b">Dosage and Administration (2.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Soybean products, such as infant formula and soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of THYQUIDITY from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c7f6731a-d0ac-4acc-a943-1b0fe765a782">
                     <id root="325b33cd-7327-26a4-e063-6294a90a7a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.10 Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7ff397d8-3922-4639-9e52-cc7de6e3d476">
               <id root="325b33cd-7328-26a4-e063-6294a90a7a4b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20230228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy may require the use of higher doses of THYQUIDITY. (
 
    <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">2.3</linkHtml>, 
 
    <linkHtml href="#LINK_055dfa0d-f871-4d76-b12d-55af7dcfc70b">8.1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_055dfa0d-f871-4d76-b12d-55af7dcfc70b">
                     <id root="325b33cd-7329-26a4-e063-6294a90a7a4b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>Risk Summary</paragraph>
                        <paragraph>Prolonged experience with levothyroxine use in pregnant women, including data from post-marketing studies, to maintain a euthyroid state have not reported increased rates of major birth defects, miscarriages, or adverse maternal or fetal outcomes
 
  <content styleCode="italics">.</content>There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and THYQUIDITY dosage adjusted during pregnancy (
 
  <content styleCode="italics">see
  
   <linkHtml href="#LINK_76e1a312-3658-49f1-a3bb-824ff26929fc">Clinical Considerations</linkHtml>)
 
  </content>. There are no animal studies conducted with levothyroxine during pregnancy. THYQUIDITY should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

 </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                     <component>
                        <section ID="LINK_76e1a312-3658-49f1-a3bb-824ff26929fc">
                           <id root="325b33cd-732a-26a4-e063-6294a90a7a4b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Clinical Considerations</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                 <br/>
                              </paragraph>
                              <paragraph>Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development. 
  <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Dose Adjustments During Pregnancy and the Postpartum Period</content>
                              </paragraph>
                              <paragraph>Pregnancy may increase THYQUIDITY requirements. Serum TSH levels should be monitored and the THYQUIDITY dosage adjusted during pregnancy to maintain TSH within normal trimester specific ranges. Since postpartum TSH levels are similar to preconception values, the THYQUIDITY dosage should return to the pre-pregnancy dose immediately after delivery 
 
  <content styleCode="italics">[see </content>
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">Dosage and Administration (2.3)</linkHtml>
                                 </content>
                                 <content styleCode="italics">].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_acbbe36f-8daa-4763-880c-67ecb15bc08d">
                     <id root="325b33cd-732b-26a4-e063-6294a90a7a4b"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>Risk Summary</paragraph>
                        <paragraph>Limited published studies report that levothyroxine is present in human milk. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for THYQUIDITY and any potential adverse effects on the breastfed infant from THYQUIDITY or from the underlying maternal condition. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9e0781b5-2d5c-4066-b626-2012142cd70f">
                     <id root="325b33cd-732c-26a4-e063-6294a90a7a4b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of THYQUIDITY has been established for the treatment of congenital hypothyroidism and acquired hypothyroidism in pediatric patients down to birth 
 
  <content styleCode="italics">[see
  
   <content styleCode="underline">
                                 <linkHtml href="#LINK_a17ac771-3438-42d9-a31e-b746f99324f4">Adverse Reactions (6)</linkHtml>
                              </content>].
 
  </content>
                        </paragraph>
                        <paragraph>Glycerol has the potential to cause gastrointestinal irritation resulting in vomiting and/or osmotic diarrhea. Patients in the first 3 months of life may be particularly susceptible to serious fluid and electrolyte complications from glycerol-induced gastrointestinal irritation. Closely monitor patients from birth to 3 months of age receiving THYQUIDITY for signs and symptoms of gastrointestinal irritation. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Congenital Hypothyroidism</content> 
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_b7670df4-1d1f-4947-9520-25e5f0643ddb">Dosage and Administration</linkHtml>
                           </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ccd47426-a2a7-41a4-a671-cc4171e11be5">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                           <br/>
                        </paragraph>
                        <paragraph>Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate THYQUIDITY therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients. 
  <br/>
                        </paragraph>
                        <paragraph>Closely monitor patients during the first 2 weeks of THYQUIDITY therapy for cardiac overload, arrhythmias, and aspiration from avid suckling.</paragraph>
                        <paragraph>Closely monitor patients to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Acquired Hypothyroidism in Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.</paragraph>
                        <paragraph>Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.</paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_edc4a133-7ee9-49df-96d9-fe5e69e854b2">
                     <id root="325b33cd-732d-26a4-e063-6294a90a7a4b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Because of the increased prevalence of cardiovascular disease among the elderly, initiate THYQUIDITY at less than the full replacement dose
 
  <content styleCode="italics">[see
  
   <content styleCode="italics">
                                 <linkHtml href="#LINK_0cf405ff-c6cf-4e5d-b10f-3c97b807a0d8">W</linkHtml>
                              </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_0cf405ff-c6cf-4e5d-b10f-3c97b807a0d8">arnings and Precautions (5.1)</linkHtml>
                              </content> 
 
  </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#LINK_93c383c2-08d0-444e-9b19-92f01f5f77f9">Dosage and Administration (2.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.

 </paragraph>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d0f93798-efb2-4b47-b48d-8cc5f9769383">
               <id root="325b33cd-732e-26a4-e063-6294a90a7a4b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The signs and symptoms of overdosage are those of hyperthyroidism
 
  <content styleCode="italics">[see</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_7ea52931-fc46-4a6d-b71e-6bd33fb5c8d7">Warnings and Precautions (5)</linkHtml> 
 
  </content>and
 
  <content styleCode="italics">
                        <linkHtml href="#LINK_a17ac771-3438-42d9-a31e-b746f99324f4">Adverse Reactions (6)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year­ old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

 </paragraph>
                  <paragraph>Reduce the THYQUIDITY dose or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status. For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.</paragraph>
               </text>
               <effectiveTime value="20230228"/>
            </section>
         </component>
         <component>
            <section ID="LINK_bd967222-3380-4e6a-a804-2f7c65800798">
               <id root="325b33cd-732f-26a4-e063-6294a90a7a4b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>THYQUIDITY (levothyroxine sodium) oral solution contains synthetic L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically identical to that produced in the human thyroid gland, and is very slightly soluble in water. Levothyroxine (T4) sodium hydrate has an empirical formula of C
 
  <sub>15</sub>H
 
  <sub>10</sub>I
 
  <sub>4</sub>NNaO
 
  <sub>4</sub>
                     <content styleCode="bold">• x</content>H
 
  <sub>2</sub>O, molecular weight of 798.85 (anhydrous), and structural formula as shown:

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>THYQUIDITY oral solution is supplied in the following strength: 100 mcg per 5 mL (20 mcg per mL). THYQUIDITY oral solution contains the inactive ingredients citric acid monohydrate, glycerin, methylparaben sodium, sodium hydroxide and purified water.</paragraph>
               </text>
               <effectiveTime value="20230228"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="thyquidity-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_368183e8-6f0b-4248-9d96-aac7f5730299">
               <id root="325b33cd-7330-26a4-e063-6294a90a7a4b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230228"/>
               <component>
                  <section ID="LINK_ed3068c7-7d33-49d0-bb6e-8f95297f3d38">
                     <id root="325b33cd-7331-26a4-e063-6294a90a7a4b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.</paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a4bba52b-fd3b-4ca6-9d07-6e95a73c8942">
                     <id root="325b33cd-7332-26a4-e063-6294a90a7a4b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_695fc817-660b-489c-a414-c05d073bd7f3">
                     <id root="325b33cd-7333-26a4-e063-6294a90a7a4b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the THYQUIDITY dose is absorbed from the jejunum and upper ileum. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and thyroxine-binding albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Thyroid hormones do not readily cross the placental barrier
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_055dfa0d-f871-4d76-b12d-55af7dcfc70b">Use in Specific Populations (8.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                           <br/>
                        </paragraph>
                        <paragraph>T4 is slowly eliminated (see Table 6). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age. 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients</content>
                        </paragraph>
                        <table width="65%" border="1" cellspacing="0" cellpadding="0">
                           <col width="97.9pt"/>
                           <col width="121.2pt"/>
                           <col width="87.7pt"/>
                           <col width="50.85pt"/>
                           <col width="111.7pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Hormone</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Ratio in Thyroglobulin</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Biologic Potency</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Half-Life (days)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Protein Binding (%)
      
       <sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Levothyroxine (T4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>10 - 20</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6-7
     
      <sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>99.96</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Liothyronine (T3)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>99.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <sup>a</sup>Includes TBG, TBPA, and TBA
    
     </paragraph>
                                    <paragraph>
                                       <sup>b</sup>3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism
    
     </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_454125f6-5a00-4c90-b19f-5e5f32e23f7e">
               <id root="325b33cd-7334-26a4-e063-6294a90a7a4b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230131"/>
               <component>
                  <section ID="LINK_f48b2518-8fcc-4298-b27d-b4bc393b20cf">
                     <id root="325b33cd-7335-26a4-e063-6294a90a7a4b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Standard animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine.</paragraph>
                     </text>
                     <effectiveTime value="20230131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_68a8c9d7-f360-44bd-bdb8-6349576881a7">
               <id root="325b33cd-7336-26a4-e063-6294a90a7a4b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>THYQUIDITY (levothyroxine sodium) oral solution, 100 mcg per 5 mL (20 mcg per mL) is a clear, colorless to nearly colorless solution supplied in a 100 mL amber glass bottle with a child-resistant closure as follows:</paragraph>
                  <paragraph>NDC 52652-1950-1: 1 x 100 mL bottle 
  <br/>  NDC 52652-1950-2: 2 x 100 mL bottles (NDC 52652-1950-1)
 </paragraph>
                  <paragraph>The pharmacy will provide a calibrated oral syringe to accurately measure the prescribed dose.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage Conditions</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                  <paragraph>Store and dispense in original bottle.  Use within 8 weeks of opening the bottle.</paragraph>
               </text>
               <effectiveTime value="20230131"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9c8712c9-3777-460c-a13c-af3da4add798">
               <id root="325b33cd-7337-26a4-e063-6294a90a7a4b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Inform the patient of the following information to aid in the safe and effective use of </content>
                     <content styleCode="bold">
                        <content styleCode="italics">THYQUIDITY:</content>
                     </content>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Dosing and Administration</content>
                     <br/>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients to take THYQUIDITY only as directed by their healthcare provider.</item>
                     <item>Instruct patients to take THYQUIDITY once daily, preferably on an empty stomach, one-half to one hour before breakfast.</item>
                     <item>Instruct patients to always use a calibrated oral syringe provided by the pharmacy when administering THYQUIDITY to ensure that the dose is measured and administered accurately.</item>
                     <item>Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take THYQUIDITY within 4 hours of these agents.</item>
                     <item>Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking THYQUIDITY.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Important Information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inform patients that it may take several weeks before they notice an improvement in symptoms.</item>
                     <item>Inform patients that the levothyroxine in THYQUIDITY is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.</item>
                     <item>Inform patients that THYQUIDITY should not be used as a primary or adjunctive therapy in a weight control program.</item>
                     <item>Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.</item>
                     <item>Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking THYQUIDITY. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.</item>
                     <item>Instruct patients to notify their physician or dentist that they are taking THYQUIDITY prior to any surgery.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Adverse Reactions</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.</item>
                     <item>Inform patients that partial hair loss may occur rarely during the first few months of THYQUIDITY therapy, but this is usually temporary.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>Azurity Pharmaceuticals, Inc. 
  <br/>  Woburn, MA 01801
 </paragraph>
                  <paragraph>For more information go to www.thyquidity.com</paragraph>
                  <paragraph>Thyquidity is a registered trademark of Azurity Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20230228"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4d016cca-36b9-4400-8c34-0ce44f66663c">
               <id root="325b33cd-7338-26a4-e063-6294a90a7a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label</title>
               <text>
                  <paragraph>NDC 52652-1950-1 
  <br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Thyquidity
  
   <sup>®</sup>
                        <br/>  (levothyroxine sodium) 
   <br/>  Oral Solution
 
  </content>
                  </paragraph>
                  <paragraph>100 micrograms/5 mL 
  <br/>  (20 micrograms/mL)
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Oral Administration Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content>Advise patients 
  <br/>  to always use a calibrated oral 
  <br/>  syringe provided by the 
  <br/>  pharmacy when using this 
  <br/>  product. Store and dispense 
  <br/>  in original bottle.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mL</content>
                  </paragraph>
                  <paragraph>azurity
 
  <sup>®</sup>
                     <br/>
                     <content styleCode="bold">pharmaceuticals</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20230228"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="thyquidity-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_43799fa4-435a-465b-b664-5df954c2ef6d">
               <id root="325b33cd-7339-26a4-e063-6294a90a7a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Carton</title>
               <text>
                  <paragraph>NDC 52652-1950-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Thyquidity
  
   <sup>®</sup>
                        <br/>  (levothyroxine sodium) 
   <br/>  Oral Solution
 
  </content>
                  </paragraph>
                  <paragraph>100 micrograms/5 mL 
  <br/>  (20 micrograms/mL)
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Oral Administration Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content>Advise patients 
  <br/>  to always use a calibrated oral 
  <br/>  syringe provided by the pharmacy 
  <br/>  when using this product.

 </paragraph>
                  <paragraph>Store and dispense in 
  <br/>  original bottle.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only 
   <br/>  azurity
  
   <sup>®</sup>
                        <br/>  pharmaceuticals
 
  </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20230228"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="thyquidity-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_89c2d758-bc20-4daf-bb14-6f98d3e983f6">
               <id root="325b33cd-733a-26a4-e063-6294a90a7a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 x 100 mL Bottle Carton</title>
               <text>
                  <paragraph>NDC 52652-1950-2</paragraph>
                  <paragraph>
                     <content styleCode="bold">Thyquidity
  
   <sup>®</sup>
                        <br/>  (levothyroxine sodium) 
   <br/>  Oral Solution
 
  </content>
                  </paragraph>
                  <paragraph>100 micrograms/5 mL 
  <br/>  (20 micrograms/mL)
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Oral Administration Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content>Advise patients to always use 
  <br/>  a calibrated oral syringe provided by the 
  <br/>  pharmacy when using this product.

 </paragraph>
                  <paragraph>Store and dispense in original bottle.</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 x 100 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only 
   <br/>  azurity
  
   <sup>®</sup>
                        <br/>  pharmaceuticals
 
  </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20230228"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 2 x 100 mL Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="thyquidity-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>